Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy.

The effect of ACE inhibition on the formation of advanced glycation end products (AGEs) and oxidative stress was explored. Streptozocin-induced diabetic animals were randomized to no treatment, the ACE inhibitor ramipril (3 mg/l), or the AGE formation inhibitor aminoguanidine (1 g/l) and followed for 12 weeks. Control groups were followed concurrently. Renal AGE accumulation, as determined by immunohistochemistry and both serum and renal fluorescence, were increased in diabetic animals. This was attenuated by both ramipril and aminoguanidine to a similar degree. Nitrotyrosine, a marker of protein oxidation, also followed a similar pattern. The receptor for AGEs, gene expression of the membrane-bound NADPH oxidase subunit gp91phox, and nuclear transcription factor-kappaB were all increased by diabetes but remained unaffected by either treatment regimen. Two other AGE receptors, AGE R2 and AGE R3, remained unchanged for the duration of the study. The present study has identified a relationship between the renin-angiotensin system and the accumulation of AGEs in experimental diabetic nephropathy that may be linked through oxidative stress

[1]  G. Jerums,et al.  The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat , 1995, Diabetologia.

[2]  W. Graier,et al.  Vascular targets of redox signalling in diabetes mellitus , 2002, Diabetologia.

[3]  Maristela L Onozato,et al.  Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. , 2002, Kidney international.

[4]  R. Cohen,et al.  High glucose via peroxynitrite causes tyrosine nitration and inactivation of prostacyclin synthase that is associated with thromboxane/prostaglandin H(2) receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. , 2002, Diabetes.

[5]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[6]  M. Cooper,et al.  Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension , 2001, Diabetologia.

[7]  A. Schmidt,et al.  Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. , 2001, American journal of physiology. Endocrinology and metabolism.

[8]  W. Hung,et al.  Role of receptor for advanced glycation end‐product (RAGE) and the JAK/STAT‐signaling pathway in AGE‐induced collagen production in NRK‐49F cells , 2001, Journal of cellular biochemistry.

[9]  G. Jerums,et al.  Ramipril and aminoguanidine restore renal lysosomal processing in streptozotocin diabetic rats , 2001, Diabetologia.

[10]  G. Jerums,et al.  Renoprotective effects of a novel inhibitor of advanced glycation , 2001, Diabetologia.

[11]  J. Egido,et al.  ACE inhibitors and AT(1) receptor antagonists-beyond the haemodynamic effect. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  Y. Kaneda,et al.  Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.

[13]  M. Ganz,et al.  AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. , 2000, American journal of physiology. Renal physiology.

[14]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[15]  S. Yusuf,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[16]  G. Jerums,et al.  Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. , 2000, Diabetes.

[17]  A. Heidland,et al.  Advanced Glycation End-Product Levels in Subtotally Nephrectomized Rats: Beneficial Effects of Angiotensin II Receptor 1 Antagonist Losartan , 1999, Mineral and Electrolyte Metabolism.

[18]  F. Murad,et al.  Nitrotyrosine formation with endotoxin-induced kidney injury detected by immunohistochemistry. , 1999, American journal of physiology. Renal physiology.

[19]  T. Miyata,et al.  Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. , 1999, Journal of the American Society of Nephrology : JASN.

[20]  Z. Makita,et al.  Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195 , 1999, Diabetologia.

[21]  G. Jerums,et al.  Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. , 1999, Kidney international.

[22]  A. Schmidt,et al.  Sp1-binding Elements in the Promoter of RAGE Are Essential for Amphoterin-mediated Gene Expression in Cultured Neuroblastoma Cells* , 1998, The Journal of Biological Chemistry.

[23]  W. Linz,et al.  Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats. , 1997, Hypertension.

[24]  S. Klahr,et al.  Enalapril decreases nuclear factor κB activation in the kidney with ureteral obstruction: Rapid Communication , 1997 .

[25]  G. Jerums,et al.  Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats , 1997, Diabetologia.

[26]  J. Malacara,et al.  Novel analytical approach to monitoring advanced glycosylation end products in human serum with on-line spectrophotometric and spectrofluorometric detection in a flow system. , 1997, Clinical chemistry.

[27]  G. King,et al.  Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. , 1997, The Journal of clinical investigation.

[28]  Y. Wada,et al.  Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. , 1997, Kidney international.

[29]  S. Klahr,et al.  Rapid communication. Enalapril decreases nuclear factor kappa B activation in the kidney with ureteral obstruction. , 1997, Kidney international.

[30]  N. Traverso,et al.  Good glycaemic control reduces oxidation and glycation end-products in collagen of diabetic rats , 1996, Diabetologia.

[31]  J S Beckman,et al.  Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. , 1996, The American journal of physiology.

[32]  G. Jerums,et al.  Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. , 1996, Kidney international.

[33]  B. Robinson,et al.  Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. , 1996, The Journal of clinical investigation.

[34]  D. Harrison,et al.  Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. , 1996, The Journal of clinical investigation.

[35]  J. Sampson The kidney in tuberous sclerosis: manifestations and molecular genetic mechanisms. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[36]  H. Kaneto,et al.  Oxidative stress caused by glycation of Cu,Zn-superoxide dismutase and its effects on intracellular components. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[37]  W. Cefalu,et al.  Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia. , 1994, Clinical chemistry.

[38]  E. Friedman,et al.  Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure , 1994, The Lancet.

[39]  J. Baynes,et al.  Glycation, Glycoxidation, and Cross-Linking of Collagen by Glucose: Kinetics, Mechanisms, and Inhibition of Late Stages of the Maillard Reaction , 1994, Diabetes.

[40]  Y. Zou,et al.  Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.

[41]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[42]  G. Wolf,et al.  Angiotensin II as a renal growth factor. , 1993, Journal of the American Society of Nephrology : JASN.

[43]  M. Mcdaniel,et al.  Prevention of Diabetic Vascular Dysfunction by Guanidines: Inhibition of Nitric Oxide Synthase Versus Advanced Glycation End-Product Formation , 1993, Diabetes.

[44]  S. Wolff Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. , 1993, British medical bulletin.

[45]  G. Jerums,et al.  Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat , 1991, Diabetes.

[46]  J. Baynes Role of Oxidative Stress in Development of Complications in Diabetes , 1991, Diabetes.

[47]  A. Cerami,et al.  Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. , 1986, Science.

[48]  B. Brenner,et al.  Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. , 1986, The Journal of clinical investigation.

[49]  S. Hsu,et al.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[50]  R. Buñag Validation in awake rats of a tail-cuff method for measuring systolic pressure. , 1973, Journal of applied physiology.

[51]  J. Hodge Dehydrated Foods, Chemistry of Browning Reactions in Model Systems , 1953 .